# Expert Assessment: CYP46A1 Overexpression Gene Therapy
## Druggability: Moderate-High but Delivery is the Problem
CYP46A1 (cholesterol 24-hydroxylase) is a well-characterized enzyme with a known crystal structure, making it a tractable target. However, traditional small-molecule activation is challenging—P450 enzymes have complex heme-dependent mechanisms. Gene therapy (AAV-mediated CYP46A1 delivery) is the proposed approach here, which sidesteps some pharmacology issues but introduces others.
Lundbeck has explored CYP46A1 inhibition rather than activation, with compounds in early development, suggesting the enzyme is indeed "druggable" but the therapeutic direction matters. Small-molecule **activators** remain largely unexplored compared to inhibitors.
## Feasibility: Significant Barriers
**Gene therapy logistics:**
- Requires BBB-penetrant AAV capsid (e.g., AAV9 variants) with neuronal tropism
- Regulatory pathway (IND) is complex—Biogen's Qalsody (tofasersen) for SOD1 ALS offers a precedent for CNS gene therapy, but approval took over a decade
- Estimated cost: $50M–$150M for IND-enabling studies; $200M–$500M through Phase III
- Timeline: 8–12 years minimum
**The 24-HC Paradox:** The skeptic raises a valid concern. Elevated CSF 24-HC is documented in AD (Hughes et al., 2014; PMID: 24619362). Whether this represents compensatory upregulation or pathological accumulation is unresolved. Overexpression could worsen neurotoxicity if elevated 24-HC is itself deleterious.
## Competitive Landscape: Crowded but Underserved
| Approach | Examples | Stage |
|----------|----------|-------|
| Anti-amyloid mAbs | Leqembi, Kisunla | Approved |
| BACE inhibitors | Verubecestat | Failed Ph III |
| LXR agonists | GW3965 (preclinical) | Stalled (TG elevation) |
| CYP46A1 inhibitors | Lundbeck compounds